SC
RNAM

Stephens Consulting’s Avidity Biosciences RNAM Stock Holding History

Stephens Consulting’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40
Closed -$1.18K – 1827
2025
Q1 		$1.18K Buy
+40
New +$1.25K ﹤0.01% 572

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stephens Consulting's RNAM Position: Q2 2025 in Review

Stephens Consulting sold out of Avidity Biosciences (RNAM) in Q2 2025, closing a stake of 40 shares — an estimated $1.18K sold.

Stephens Consulting first reported a position in RNAM in Q1 2025 and held it in 1 quarter. The position peaked at $1.18K in Q1 2025. 206 funds tracked by Wall St. Rank hold RNAM as of Q2 2025.

  • Stephens Consulting reported no remaining Avidity Biosciences position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 40 Avidity Biosciences shares in Q2 2025, an estimated $1.18K.
  • Stephens Consulting first reported a position in Avidity Biosciences in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Avidity Biosciences position peaked at $1.18K in Q1 2025.
  • 206 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.